Clinical Trial Update: A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 CAR-T trial for relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CAR-T therapy (Chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Guangzhou Bio-gene Technology Co., Ltd | Conditions: T-Cell Acute Lymphocytic Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN